Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019
Open Access
- 11 September 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Cellular & Molecular Immunology
- Vol. 17 (10), 1092-1094
- https://doi.org/10.1038/s41423-020-00522-6
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81773045)
- Scientific and Technological Emergency Projects of Henan Province for Prevention and Control of COVID-19
This publication has 11 references indexed in Scilit:
- Effective treatment of severe COVID-19 patients with tocilizumabProceedings of the National Academy of Sciences of the United States of America, 2020
- Clinical and immunological features of severe and moderate coronavirus disease 2019JCI Insight, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- IL-6 as a keystone cytokine in health and diseaseNature Immunology, 2015
- Increased plasma levels of interleukin-6 in sepsis.1989
- Increased plasma levels of interleukin-6 in sepsis [see comments]Blood, 1989